^
    Back
    Association details:
    Biomarker:APOBEC mutagenesis
    Cancer:Urothelial Cancer
    Drug:Tecentriq (atezolizumab) (PD-L1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    ASCO 2020
    Title:

    Tumor, immune, and stromal characteristics associated with clinical outcomes with atezolizumab (atezo) + platinum-based chemotherapy (PBC) or atezo monotherapy (mono) versus PBC in metastatic urothelial cancer (mUC) from the phase III IMvigor130 study.

    Published date:
    05/13/2020
    Excerpt:
    APOBEC mutagenesis was associated with improved OS with atezo-containing regimens…
    DOI:
    10.1200/JCO.2020.38.15_suppl.5011
    Trial ID:
    IMvigor130
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Front Oncol
    Title:

    APOBEC Mutational Signature and Tumor Mutational Burden as Predictors of Clinical Outcomes and Treatment Response in Patients With Advanced Urothelial Cancer

    Published date:
    03/07/2022
    Excerpt:
    We retrospectively reviewed consecutive UC cases assessed with UCSF500....Patients with APOBEC (N=16) were compared with remaining 56 patients, comprised of 27 NHM patients and 29 patients with unknown TMB, showing APOBEC patients to have improved OS from diagnosis (125.3 months vs 44.5 months, p=0.05) but inferior OS for patients treated with chemotherapy (7.0 months vs 13.1 months, p=0.05)....APOBEC patients had a longer median OS from initial diagnosis relative to Other patients (125.3 months vs 44.5 months, p = 0.05) (Figure 3A and Table 4)…APOBEC patients had numerically higher ORR to IO treatment (4/7, 57%), relative to evaluable Other patients (8/25, 32%)...APOBEC patients received Pembrolizumab (5/8, 63%) and Atezolizumab (3/8, 38%)...
    DOI:
    https://doi.org/10.3389/fonc.2022.816706